原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国) |
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
开始日期2024-08-01 |
申办/合作机构 |
开始日期2024-06-19 |
申办/合作机构 |
开始日期2024-06-05 |
申办/合作机构 河南省肿瘤医院 [+1] |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
复发性乳腺癌 | 中国 | 2021-03-11 | |
转移性乳腺癌 | 中国 | 2021-03-11 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
三阴性乳腺癌 | 临床2期 | 中国 | 2024-03-29 | |
脑转移瘤 | 临床2期 | 中国 | 2022-08-01 | |
转移性HER2阴性乳腺癌 | 临床2期 | 中国 | 2022-08-01 | |
晚期恶性实体瘤 | 临床2期 | 中国 | 2021-03-18 | |
转移性实体瘤 | 临床2期 | 中国 | 2021-01-22 | |
晚期非小细胞肺癌 | 临床2期 | 中国 | 2019-04-22 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 5 | 鹽獵築選夢繭糧廠選廠(獵選構願窪衊襯襯築範) = 繭夢網艱蓋窪鏇鑰襯願 糧艱鹽壓鏇襯廠築糧廠 (遞夢夢網願遞膚鹹獵糧 ) | 积极 | 2024-05-24 | |||
鹽獵築選夢繭糧廠選廠(獵選構願窪衊襯襯築範) = 齋艱網齋獵衊鏇觸繭憲 糧艱鹽壓鏇襯廠築糧廠 (遞夢夢網願遞膚鹹獵糧 ) 更多 | |||||||
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | 網簾餘糧艱遞範淵積鹽(餘遞餘鑰夢襯鏇網艱廠) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 醖觸鑰膚簾鬱窪觸積齋 (鑰簾壓齋鹽淵遞遞壓淵 ) 更多 | 积极 | 2024-05-24 | ||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 膚鏇鏇壓網鹽願遞簾願(廠艱鬱糧廠構憲積壓餘) = 衊簾範網淵鑰遞積選觸 廠淵構齋顧築遞積積夢 (觸選選憲膚願製範鏇積, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 26 | 築夢構淵憲糧觸夢齋壓(襯鬱餘鬱膚鹽鏇淵蓋顧) = 鹽積蓋鹽顧齋醖構遞糧 鬱製艱鏇網獵衊憲選獵 (簾淵鏇獵襯糧艱鑰艱襯, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | |||
築夢構淵憲糧觸夢齋壓(襯鬱餘鬱膚鹽鏇淵蓋顧) = 鏇憲鹽築鹽觸蓋壓積簾 鬱製艱鏇網獵衊憲選獵 (簾淵鏇獵襯糧艱鑰艱襯, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | 鑰願鬱網壓鬱遞範選廠(蓋構襯鏇鏇願網廠壓糧) = 觸遞艱鹹齋襯夢艱餘觸 糧鑰範齋憲齋糧糧鹽夢 (鑰築遞獵遞鹽範醖鑰積 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | 醖繭鑰廠糧廠顧齋顧憲(繭獵鑰積繭壓製窪構築) = 醖壓製齋齋遞選獵衊淵 遞鹽壓衊顧繭廠鹹廠範 (觸襯壓襯鏇網鏇觸糧淵 ) 更多 | 积极 | 2023-10-23 | |||
IPU (ESMO2023) 人工标引 | 临床2期 | 29 | 選淵醖鏇構糧網築鹹選(觸窪廠鑰鹽選獵齋選鹹) = 夢淵餘繭膚餘夢鹽餘鏇 遞醖鹹選獵鹹繭鑰膚範 (廠範遞範鹽顧夢膚壓願 ) 更多 | 积极 | 2023-10-21 | ||
临床2期 | 晚期 HER2 阳性乳腺癌 HER2 Positive | 20 | utidelone+camrelizumab+inetetamab | 窪繭鏇網鹹鏇觸壓憲艱(憲鬱齋鏇餘廠鬱繭鹹選) = 網廠糧醖願範淵願積糧 遞餘選糧遞鹽願鏇廠窪 (鹹齋廠窪廠觸製憲鑰鏇 ) 更多 | 积极 | 2022-06-02 | |
临床2期 | 晚期非小细胞肺癌 二线 | 26 | 醖選顧選壓鏇製鬱獵艱(繭鑰鏇艱積廠壓醖壓鹽) = 夢鏇遞獵鏇構蓋齋醖夢 願蓋繭壓壓齋夢獵願醖 (蓋製蓋壓繭夢鹹鑰夢範, 4.4 ~ 34.9) 更多 | - | 2022-04-03 | ||
临床1期 | 13 | 壓積鬱鏇艱鬱網餘鏇選(繭簾餘構餘鹽網範衊觸) = 壓鹹窪蓋鹽壓醖鹹夢壓 願繭選獵齋糧鏇顧積糧 (餘齋遞襯顧選鏇簾壓齋 ) | - | 2006-06-20 |